Additionally, KAT2A expression was significantly higher in stage II tumors compared to stage I, while no significant difference was detected between stages III/IV and stage I. When evaluating clinical features, we found distinct expression patterns associated with patient demographics and tumor characteristics. Here, KAT2A is linked to neoplasm.